ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025

blonca9
Dec 8, 2024
1 min read

He comments on data at ASH including tafasitamab, axitilimab, and the company's BET inhibitor. Plus, news from yesterday on Incyte's PD1, and looking forward to next year.

Recent Posts

See All

NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity

With a phase 3 trial for its PRAME cell therapy underway and a data update coming up at ASCO, Immatics is pushing to be a leader in TCR based cell therapies and T-cell engagers

Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals

ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight